Finch Therapeutics Group (Finch Therapeutics Group) Forward Dividend Yield % : 0.00% (As of Jun. 07, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Finch Therapeutics Group Forward Dividend Yield %?

As of today (2024-06-07), the Forward Annual Dividend Yield of Finch Therapeutics Group is 0.00%.

As of today (2024-06-07), the Trailing Annual Dividend Yield of Finch Therapeutics Group is 0.00%.

FNCH's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.63
* Ranked among companies with meaningful Forward Dividend Yield % only.

Finch Therapeutics Group's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Finch Therapeutics Group's Forward Dividend Yield %

For the Biotechnology subindustry, Finch Therapeutics Group's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Finch Therapeutics Group's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Finch Therapeutics Group's Forward Dividend Yield % falls into.

Finch Therapeutics Group Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Finch Therapeutics Group (OTCPK:FNCH) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Finch Therapeutics Group Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Finch Therapeutics Group's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Finch Therapeutics Group (Finch Therapeutics Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Finch Therapeutics Group Inc (OTCPK:FNCH) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Inner Belt Road, Suite 400, Somerville, MA, USA, 02143

Website

https://www.finchtherapeutics.com

Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.

Executives

Jeffery A Smisek	director	1600 SMITH STREET, HQSEO, HOUSTON TX 77002
Susan E Graf	director	400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Lance E Thibault	officer: Chief Financial Officer
Matthew P. Blischak	officer: Chief Executive Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SOMERVILLE MA 02143
Joseph Vittiglio	officer: Chief Business & Legal Officer	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Marc Blaustein	officer: Chief Operating Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Domenic J Ferrante	director	BROOKSIDE CAPITAL MANAGEMENT LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Samuel A Hamood	director	C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Joanne L. Viney	director	C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Nicholas Haft	director	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Christian H. Lange	director	28 HAVEMEYER PLACE, GREENWICH CT 06830
Crestovo Investor Llc	director, 10 percent owner	28 HAVEMEYER PLACE, GREENWICH CT 06830
Gregory D Perry	officer: Chief Financial Officer	C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Chris Shumway	director, 10 percent owner	28 HAVEMEYER PLACE, GREENWICH CT 06830
Zain Kassam	officer: Chief Medical Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143